A Clinical Hepatologist's Predictions about Non-Absorbed Carbohydrates for the Early Twenty-First Century

REFERENCES

• Montgomery E, Hudson CS. Transformation of lactose to a new disaccharide, lactoketose. Science 1929;69: 556.
   Google Scholar
• Ingelfinger F. Editorial comments. In: Beeson PB et al, editors. Year book of medicine. Chicago: Year Book Medical Publishers 1964–1965:591–2.
   Google Scholar
• Bircher J, Gmünder U, Haemmerli UP, Haemmerli G, Bally G, Muller-Duysing W, Hoffmann K. Determination of colonic bacterial flora and urease activity during lactulose therapy in rats. Symposium on Lactulose. Baden bei Wein, Austria, September 8, 1969.
   Google Scholar
• Hoffman K, Bircher J, Haemmerli UP. Correlation of changes in fecal flora, fecal pH and fecal ammonia. Symposium on Lactulose. Baden bei Wein, Austria, September 8, 1969.
   Google Scholar
• Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double-blind controlled trial. Gastroenterology 1977;72: 573–83.
   PubMed Web of Science ®Google Scholar
• Heredia D, Caballería J, Arroyo V, et al. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE): a controlled trial. J Hepatol 1987;4: 293–8.
   PubMed Web of Science ®Google Scholar
• Mortensen PB, Holtug K, Bonnen H, et al. The degradation of amino acids, proteins and blood to short-chain fatty acids in colon is prevented by lactulose. Gastroenterology 1990;98: 353–60.
   PubMed Web of Science ®Google Scholar
• Vince A, Killingley M, Wrong OM. Effect of lactulose on ammonia production in a fecal incubation system. Gastroenterology 1978;74: 544–9.
   PubMed Web of Science ®Google Scholar
• MacGillivray PC, Finlay II VL, Binns TB. Use of lactulose to create a preponderance of lactobacilli in the intestine of bottle-fed infants. Scot Med J 1959;4: 182–9.
   PubMedGoogle Scholar
• Levitt MD, Hirsh P, Fetzer CA, et al. H2 excretion after ingestion of complex carbohydrates. Gastroenterology 1987;92: 383–9.
   PubMed Web of Science ®Google Scholar
• Florent C. Colonic metabolism of lactulose in man. In: Conn HO, Bircher J, editors. Hepatic encephalopathy syndromes and therapies. Bloomington, IL 1994: 149–62.
   Google Scholar
• Bircher J, Ullrich D. Clinical pharmacology of lactulose, lactitol and related disaccharides. In: Conn HO, Bircher J, editors. Hepatic encephalopathy syndromes and therapies. Bloomington, IL 1994: 195–202.
   Google Scholar
• Wesselius-De Casparis A, Braadbaart S, Bergh-Bohlken GE, et al. Treatment of chronic constipation with lactulose syrup: results of a double-blind study. Gut 1968;9: 84–6.
   PubMed Web of Science ®Google Scholar
• London NJM, Bramley PD, Windle R. Effect of four days of postoperative lactulose on posthemorrhoidectomy pain: results of placebo controlled trial. Br Med J 1987;295: 363–4.
   PubMedGoogle Scholar
• Sander-Treske R, Czermak L. Lactulose in Salmonella enteritis—an alternative to antibiotic chemotherapy. Therapiewoche 1976;26: 740–5.
   Google Scholar
• McCutcheon J, Fulton JD. Lowered prevalence of infection with lactulose therapy in patients in long-term hospital care. J Hosp Infect 1989;13: 81–6.
   PubMed Web of Science ®Google Scholar
• Mack KJ, Smart L, Girdwood A, et al. Prevention of hospital infection in geriatrics with lactulose. In: Lactulose: classical indications and future option. European Association for the study of the liver satellite symposium. Vienna, Austria, 26 August, 1992.
   Google Scholar
• Paumgartner G, Sauerbruch T. Gallstones: pathogenesis. Lancet 1991;338: 1117–21.
   PubMed Web of Science ®Google Scholar
• Marcus SN, Heaton KW. Deoxycholic acid and the pathogenesis of gallstones. Gut 1988;29: 522–33.
   PubMed Web of Science ®Google Scholar
• Berr F, Pratschke E, Fischer S, Paumgartner G. Disorders of bile acid metabolism in cholesterol gallstone disease. J Clin Invest 1992;90: 859–68.
   PubMed Web of Science ®Google Scholar
• Thornton JR, Heaton KW. Do colonic bacteria contribute to cholesterol gall-stone formation? Effects of lactulose on bile. Br Med J 1981;282: 1018–20.
   PubMed Web of Science ®Google Scholar
• Wechsler JG, Wenzel H, Swobodnik W, Ditschuneit H. Influence of increased fibre intake on biliary lipids. Scand J Gastroenterol 1987;22 Suppl 129: 185–91.
   Google Scholar
• Van Berge Henegouwen GP, Van Der Werf SDJ, Reuben ATh. Effect of long term lactulose ingestion on secondary bile salt metabolism in man: potential protective effect of lactulose in colonic carcinogenesis. Gut 1987;28: 675–80.
   PubMed Web of Science ®Google Scholar
• Nagengast FM, Hectors MPC, Buys WAM, et al. Inhibition of secondary bile acid formation in the large intestine by lactulose in healthy subjects of two different age groups. Eur J Clin Invest 1988;18: 56–61.
   PubMed Web of Science ®Google Scholar
• Samelson SL, Nelson RL, Nyhuis LM. Protective role of faecal pH in experimental colon carcinogenesis. J R Soc Med 1985;78: 230–3.
   PubMed Web of Science ®Google Scholar
• Ponz de Leon M, Di Donato P, Roncucci L, et al. Lactulose and antioxidant vitamins in the prevention of the recurrence of adenomatous polyps. In: Conn HO, Bircher J, editors. Hepatic encephalopathy: management with lactulose and related carbohydrates. Bloomington, IL: Medi-Ed Press, 1988: 343–9.
   Google Scholar
• Roncucci L, Di Donato P, Carati L, et al. Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Dis Colon Rectum 1993;67: 227–34.
   Google Scholar
• Liehr H, Englisch G, Rasenack U. Lactulose—a drug with antiendotoxin effect. Hepatogastroenterology 1980;27: 356–60.
   PubMed Web of Science ®Google Scholar
• de Groote GH, Schalm SW, Batavier P, et al. Incidence of endotoxaemia in pigs with ischaemic hepatic necrosis treated by haemodialysis. Prevention of endotoxaemia with lactulose. Hepatogastroenterology 1983;30: 240–2.
   PubMed Web of Science ®Google Scholar
• Pain JA, Bailey ME. Experimental and clinical study of lactulose in obstructive jaundice. Br J Surg 1986;73: 775–8.
   PubMed Web of Science ®Google Scholar
• Pain JA, Cahill CJ, Gilbert JM, et al. Prevention of postoperative renal dysfunction in patients with obstructive jaundice: a multicentre study of bile salts and lactulose. Br J Surg 1991;78: 467–9.
   PubMed Web of Science ®Google Scholar
• Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;2: 639–43.
   Google Scholar
• Zieve FJ, Zieve D, Doizaki WM, Gilsdorf RB. Synergism between ammonia and fatty acids in the production of coma: implications for hepatic coma. J Pharmacol Exp Ther 1974;191: 10–6.
   PubMed Web of Science ®Google Scholar
• Merino GE, Jetzer T, Doizaki WMD, Najarian JS. Methionine-induced hepatic coma in dogs. Am J Surg 1975;130: 41–6.
   PubMed Web of Science ®Google Scholar
• Chen S, Zieve L, Mahadevan V. Mercaptans and methylsulfide in the breath of patients with cirrhosis of the liver. J Lab Clin Med 1970;75: 628–35.
   PubMed Web of Science ®Google Scholar
• Doizaki WM, Zieve L. An improved method for measuring blood mercaptans. J Lab Clin Med 1977;90: 849–55.
   PubMed Web of Science ®Google Scholar
• Zieve L, Doizaki WM, Zieve FJ. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 1974;83: 16–28.
   PubMed Web of Science ®Google Scholar
• Campollo O, Cortéz R, Gutiérrez M, et al. Sodium benzoate and lactulose for the treatment of hepatic encephalopathy. J Hepatol 1994;21: 1144–57.
   PubMed Web of Science ®Google Scholar
• Kirchels G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled double-blind study. Hepatology 1997. (In press).
   Google Scholar
• Pedretti G, Calzetti C, Missale C, et al. Rifaximin versus neomycin on hyperammonemia in chronic portal-systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991;23: 175–8.
   Web of Science ®Google Scholar
• Parini P, Cipolla A, Ronchi M, et al. Effect of nifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992;52: 34–9.
   Web of Science ®Google Scholar
• Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993: 109–18.
   Google Scholar
• Pomier-Layrargues G, Giguère JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled trial. J Hepatology 1994;19: 32–7.
   Google Scholar
• Eriksson LS, Conn HO. Branched chain amino acids in the management of hepatic encephalopathy: an analysis of variants. Hepatology 1989;10: 228–46.
   PubMed Web of Science ®Google Scholar
• Naylor CD. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989;97: 1033–42.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Dioguardi FS, Bianchi GP, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. J Hepatol 1990;11: 92–107.
   PubMed Web of Science ®Google Scholar
• Uribe M, Marquez MA, Ramos GG, et al. Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets. A controlled-crossover study. Dig Dis Sci 1982; 27: 1109–16.
   PubMed Web of Science ®Google Scholar
• Grungreiff K, Franke D, Lobner B. Zinc deficiency—a factor in the pathogenesis of hepatic encephalopathy? Z Gastroenterol 1991;29: 101–6.
   PubMedGoogle Scholar
• Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J. Med 1993;2: 414–6.
   Google Scholar
• Riggio O, Merli M, Capocaccia L. Zinc supplementation reduces blood ammonia and increases liver ornithine transcar- bamylase activity in experimental cirrhosis. Hepatology 1992; 16: 785–9.
   PubMed Web of Science ®Google Scholar
• Zavagli G, Ricci G, Bader G, et al. The importance of the highest normokalemia in the treatment of early hepatic encephalopathy. Minerva Electrolyte Metab 1993;19: 362–7.
   PubMedGoogle Scholar